Abstract
We have developed a method that uses energetic analysis of structure-based fragment docking to elucidate key features for molecular recognition. This hybrid ligand- and structure-based methodology uses an atomic breakdown of the energy terms from the Glide XP scoring function to locate key pharmacophoric features from the docked fragments. First, we show that Glide accurately docks fragments, producing a root mean squared deviation (RMSD) of <1.0 Å for the top scoring pose to the native crystal structure. We then describe fragment-specific docking settings developed to generate poses that explore every pocket of a binding site while maintaining the docking accuracy of the top scoring pose. Next, we describe how the energy terms from the Glide XP scoring function are mapped onto pharmacophore sites from the docked fragments in order to rank their importance for binding. Using this energetic analysis we show that the most energetically favorable pharmacophore sites are consistent with features from known tight binding compounds. Finally, we describe a method to use the energetically selected sites from fragment docking to develop a pharmacophore hypothesis that can be used in virtual database screening to retrieve diverse compounds. We find that this method produces viable hypotheses that are consistent with known active compounds. In addition to retrieving diverse compounds that are not biased by the co-crystallized ligand, the method is able to recover known active compounds from a database screen, with an average enrichment of 8.1 in the top 1% of the database.
Similar content being viewed by others
References
Erlanson DA, McDowell RS, O’Brien T (2004) J Med Chem 47:3463. doi:10.1021/jm040031v
Boehm H-J, Boehringer M, Bur D, Gmuender H, Huber W, Klaus W, Kostrewa D, Kuehne H, Luebbers T, Meunier-Keller N, Mueller F (2000) J Med Chem 43:2664. doi:10.1021/jm000017s
Gill A (2004) Mini Rev Med Chem 4:301. doi:10.2174/1389557043487385
Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim S-H, Schlessinger J, Zhang KYJ (2005) Nat Biotechnol 23:201. doi:10.1038/nbt1059
Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H (2005) J Med Chem 48:403. doi:10.1021/jm0495778
Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J (2000) Nat Biotechnol 18:1105. doi:10.1038/80319
Tondi D, Morandi F, Bonnet R, Costi MP, Shoichet BK (2005) J Am Chem Soc 127:4632. doi:10.1021/ja042984o
Hajduk PJ, Greer J (2007) Nat Rev Drug Discov 6:211. doi:10.1038/nrd2220
Tobias Fink HB, Reymond J (2005) Angew Chem 117:1528. doi:10.1002/ange.200462457
Martin YC (1981) J Med Chem 24:229. doi:10.1021/jm00135a001
Babaoglu K, Shoichet BK (2006) Nat Chem Biol 2:720. doi:10.1038/nchembio831
Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) J Med Chem 49:534. doi:10.1021/jm050540c
Moitessier N, Therrien E, Hanessian S (2006) J Med Chem 49:5885
Nabuurs SB, Wagener M, de Vlieg J (2007) J Med Chem 50:6507
Zhou Z, Felts AK, Friesner RA, Levy RM (2007) J Chem Inf Model 47:1599
Perola E, Walters WP, Charifson PS (2004) Proteins 56:235
Marcou G, Rognan D (2007) J Chem Inf Model 47:195
Cole JC, Murray CW, Nissink JW, Taylor RD, Taylor R (2005) Proteins 60:325
Deng Z, Chuaqui C, Singh J (2004) J Med Chem 47:337
Yusuf D, Davis AM, Kleywegt GJ, Schmitt S (2008) J Chem Inf Model 48:1411
Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) J Med Chem 49:6177
Schrödinger Fragment Library (2008) Schrödinger, Inc. http://www.schrodinger.com/ProductInfo.php?mID=6&sID=6&cID=53
Bemis GWM, Murcko MA (1996) J Med Chem 39:7
Fejzo J, Lepre CA, Peng JW, Bemis GW, Ajay, Murcko MA, Moore JM (1999) Chem Biol 6:755
Huth JR, Sun C (2002) Comb Chem High Throughput Screen 5:631
Hajduk PJ, Bures M, Praestgaard J, Fesik SW (2000) J Med Chem 43:3443
Jacoby E, Davies J, Blommers MJJ (2003) Curr Top Med Chem 3:11
Maestro v8.5, Schrödinger, Inc.: Portland, OR
Impact v5.0, Schrödinger, Inc.: Portland, OR
LigPrep v2.2, Schrödinger, Inc.: Portland, OR
Epik v1.6, Schrödinger, Inc.: Portland, OR
Glide v5.0, Schrödinger, Inc.: Portland, OR
Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) Proc Natl Acad Sci USA 96:9997
Volume_cluster.py from the Schrödinger ScriptCenter (2008) Schrödinger, Inc. http://www.schrodinger.com/ScriptCenter.php
Phase v3.0, Schrödinger, Inc.: Portland, OR
Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) J Comput-Aided Mol Des 11:425
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) J Med Chem 47:1750
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) J Med Chem 47:1739
Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ (1998) Structure 39:12
Dixon S, Smondyrev A, Knoll E, Rao S, Shaw D, Friesner R (2006) J Comput-Aided Mol Des 20:647
Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) J Med Chem 51:3661
Damm KL, Carlson HA (2006) Biophys J 90:4558
Meyer EA, Furler M, Diederich F, Brenk R, Klebe G (2004) Helv Chim Acta 87:1333
Wu Q, Gee CL, Lin F, Tyndall JD, Martin JL, Grunewald GL, McLeish MJ (2005) J Med Chem 48:7243
Canvas v1.1, Schrödinger, Inc.: Portland, OR
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Loving, K., Salam, N.K. & Sherman, W. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23, 541–554 (2009). https://doi.org/10.1007/s10822-009-9268-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-009-9268-1